The milestones in xenotransplantation – cross-species transplants – rely on cutting-edge biotechnologies, including the use ...

Interim data from the 393-patient phase 3 CERVINO trial of etentamig (ABBV-383), a bispecific CD3 and BCMA-directed TCE, ...

The discovery by the UK Health Security Agency (UKHSA) raises the possibility that viral diseases that are known to be ...

Ionis' antisense therapy Zanvastro has been approved by the FDA for Alexander disease (AxD), throwing a lifeline to people ...

Denmark's Netcompany has been awarded a five-year contract from NHS England, worth more than £215 million, to build the ...

Eli Lilly has raised the stakes in its rivalry with Novo Nordisk on GLP-1 agonists for diabetes, with new data for Mounjaro on cardiovascular outcomes. The results of the SURPASS-CVOT trial showed ...

Shares in China's Hutchmed surged today after GSK paid $110 million upfront for rights to a preclinical-stage KRAS and EGFR-targeted drug with potential in colorectal, pancreatic, and lung cancer.

Shares in rare disease specialist Ultragenyx lost nearly 47% of their value after the announcement, more than wiping out ...

PMV Pharma is preparing to file for approval of its oral p53 protein reactivator drug rezatopopt in the first quarter of 2027 ...

The US Advanced Research Projects Agency for Health (ARPA-H) has awarded $125 million in funding, split across five groups, ...

The US FDA issued similar warning letters to five different online peptide vendors on 24th August, giving the companies 15 ...

Novartis' oral BTK inhibitor remibrutinib has shown efficacy in a pair of phase 3 trials in relapsing multiple sclerosis (RMS ...